Search - tctmd.com

Displaying 41 - 60 of 105

Sort: Relevancy | Date

News Daily News

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

L.A. McKeown

March 27, 2023

News Daily News

Study Debunks Obesity Paradox in HF, Encourages BMI Alternatives

L.A. McKeown

March 24, 2023

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

Todd Neale

March 15, 2023

News Opinion Editor's Corner

The Biggest News of 2022: TCTMD’s Top 10

Shelley Wood

December 30, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

Less Occlusion, Hematomas With Distal Radial Access: Meta-analysis

Michael O'Riordan

November 22, 2022

News Conference News TCT 2022

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

Yael L. Maxwell

September 19, 2022

News Daily News

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

Caitlin E. Cox

September 09, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2022

Todd Neale

August 01, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2022

Shelley Wood

June 01, 2022

News Conference News ESC Heart Failure 2022

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

Shelley Wood

May 25, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

SODIUM-HF: No Impact of Dietary Salt Restriction on Death or Hospitalization

News Conference News ACC 2022

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

L.A. McKeown

April 02, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Opinion CV Team Dispatch

April 2022 News Roundup

L.A. McKeown

April 01, 2022

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

L.A. McKeown

March 22, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

L.A. McKeown

February 07, 2022

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

Advertisement

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

Study Debunks Obesity Paradox in HF, Encourages BMI Alternatives

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

The Biggest News of 2022: TCTMD’s Top 10

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Less Occlusion, Hematomas With Distal Radial Access: Meta-analysis

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

What’s Going to Be Hot at ESC 2022?

TCTMD’s Top 10 Most Popular Stories for July 2022

TCTMD’s Top 10 Most Popular Stories for May 2022

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 2022 News Roundup

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

FDA Approves Empagliflozin for Treatment of HFpEF

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content